New drug ABBV-547 enters first human tests
NCT ID NCT07232004
First seen Nov 17, 2025 · Last updated May 19, 2026 · Updated 24 times
Summary
This early-stage study tests the safety and tolerability of a single dose of ABBV-547 in about 87 healthy adults in the US and Japan. Participants are randomly assigned to receive either the drug or a placebo. The study monitors side effects and how the drug moves through the body. It is not intended to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 278638
RECRUITINGGrayslake, Illinois, 60030, United States
-
CenExel ACT- Anaheim Clinical Trials /ID# 279612
RECRUITINGAnaheim, California, 92801, United States
Conditions
Explore the condition pages connected to this study.